-
Xianning Market Supervision Administration Food Safety Supervision and Sampling Information Announcement (Issue 19, 2022
Time of Update: 2022-12-29
According to the Food Safety Law of the People's Republic of China, the Xianning Municipal Administration for Market Supervision recently organized supervision and sampling inspection of 43 batches of biscuits, catering foods, starch and starch products, condiments, convenience foods, pastries, grain processing products, dairy products, edible oils, oils and fats and their products, potatoes and puffed foods, quick-frozen foods and beverages.
-
Five new varieties of food additives such as sodium sulfide pentahydrate solicit opinions
Time of Update: 2022-09-03
News from this newspaper (reporter Yang Xiaojing) A few days ago, it was learned from the National Food Safety Risk Assessment Center that three new varieties of enzyme preparations for food industry
-
JAMA neurology: Comparison of the effects of different hormone therapy options in patients with severe muscle weakness
Time of Update: 2021-02-24
The two groups of patients were randomly assigned to the slow reduction group (strong pine dose gradually increased to 1.5 mg/kg, once the MG remission state is reached, slowly decreased) and the rapid treatment group (immediately after diagnosis, the daily high dose of strong pine 0.75 mg/kg administration, once the MG improved state, the dose is reduced rapidly in advance).
-
CheckMate-870 results are positive: Odivor (Navuliu monotophosm) is safe and reliable in patients with advanced or metastatic non-small cell lung cancer (NSCLC
Time of Update: 2020-07-14
On June 30, 2020, The Results of CheckMate-870 were presented at the American Association for Cancer Research's Annual Meeting (AACR 2020) CheckMate-870 is an open-label phase IIIB clinical study de
-
Core results of TransCon parathyroid global Phase II clinical study announced
Time of Update: 2020-06-06
Ascendis Pharma announced on April 19, 2020 that positive results were achieved in a 4-week fixed-dose double-blind phase of a global Phase II clinical study (PaTH Forward Study) that assessed the saf
